Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin B pseudogene 2 (UBBP2) is a processed pseudogene derived from the Ubiquitin B (UBB) gene, formed by reverse transcription and reinsertion into the genome[5]. Processed pseudogenes like UBBP2 lack regulatory regions and typically do not produce functional proteins. While the canonical ubiquitin genes (such as UBB) play essential roles in protein degradation, gene regulation, and disease, current evidence does not support functional translation or biological activity for UBBP2. To date, only UBB pseudogene 4 (UBBP4) shows evidence for protein coding and alternative biological functions among the UBB pseudogene family[4]. UBBP2 is not a druggable or therapeutic target. The only UBB pseudogene with experimental evidence of translation and cellular activity is UBBP4 (“KEKS” variant), not UBBP2[4]. There is no evidence for UBBP2's expression or functional protein product, nor for any disease or molecular pathway association.
null
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin B pseudogene 2 (UBBP2).